2023 Pediatric Rheumatology Symposium

March 29-April 1, 2023. New Orleans, LA.

View by Number View by Title View Sessions

View by Date

Friday, March 31, 2023

2:30PM-3:00PM: Abstract Number: 006

Implementation of Automated Depression Screening in Patients with Lupus in a Tertiary Pediatric Rheumatology Clinic

Plenary Abstracts Session II

2:30PM-3:00PM: Abstract Number: 005

Real-World Application of the Pediatric Glucocorticoid Toxicity Index in Children with Lupus Nephritis: A Feasibility and Initial Validation Study

Plenary Abstracts Session II

4:30PM-5:00PM: Abstract Number: 028

Achieving Medication-Free Remission in Juvenile Dermatomyositis

Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects

4:30PM-5:00PM: Abstract Number: 029

Cardiac Magnetic Resonance Imaging in Children with Systemic Lupus Erythematosus and Scleroderma Spectrum Disorders: A Single Center Experience

Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects

4:30PM-5:00PM: Abstract Number: 032

From Bedside to Bench and Back: Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes with Hearing Loss as the Primary Presentation, Responsive to Anti-IL1 Therapy

Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

4:30PM-5:00PM: Abstract Number: 040

HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis

Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States

4:30PM-5:00PM: Abstract Number: 038

HLA-DRB1*15 Alleles in Systemic Juvenile Idiopathic Arthritis with Lung Disease and Macrophage Activation Syndrome in Italy

Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States

4:30PM-5:00PM: Abstract Number: 027

Identifying and Understanding JDM in Africa: A Survey of Rheumatology Care Providers from Africa

Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects

4:30PM-5:00PM: Abstract Number: 030

International Validation of the Total Morbidity Score for Juvenile Localized Scleroderma: 2023 Update

Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects

4:30PM-5:00PM: Abstract Number: 033

Kawasaki Disease (KD) Criteria Fulfillment and Associated Outcomes in Multisystem Inflammatory Syndrome in Children (MIS-C)

Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

4:30PM-5:00PM: Abstract Number: 031

Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants

Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

4:30PM-5:00PM: Abstract Number: 026

Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 Instrument in a Juvenile Systemic Sclerosis Cohort

Poster Breakout 4 - JDM & Scleroderma: Clinical & Therapeutic Aspects

4:30PM-5:00PM: Abstract Number: 036

Predictive Factors of Long-lasting Remission Following Anakinra Withdrawal in Patients with Systemic Juvenile Idiopathic Arthritis After Achievement of Clinical Inactive Disease

Poster Breakout 6 - Systemic JIA: Genomics, Transcriptomics & Disease States

4:30PM-5:00PM: Abstract Number: 035

SARS-CoV-2 Vaccination of Children with a History of Multisystem Inflammatory Syndrome

Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

4:30PM-5:00PM: Abstract Number: 034

STAT3 Gain-of-function Syndrome Mutations Are Susceptible to JAK Inhibition Despite a Spectrum of Potency

Poster Breakout 5 - Autoinflammatory/Vasculitis: STAT3, NLRP3, KD and MIS-C

1
2
3
…
5
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].